Gemma Azaceta

496 total citations
19 papers, 275 citations indexed

About

Gemma Azaceta is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Gemma Azaceta has authored 19 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Gemma Azaceta's work include Immune Cell Function and Interaction (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Gemma Azaceta is often cited by papers focused on Immune Cell Function and Interaction (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Gemma Azaceta collaborates with scholars based in Spain, France and Germany. Gemma Azaceta's co-authors include Luis Palomera, Isabel Marzo, Alberto Anel, Javier Naval, Marı́a Contel, Laura Vela, Julián Pardo, Martín Villalba, Diego Sánchez‐Martínez and Carlos Vilches and has published in prestigious journals such as Blood, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Gemma Azaceta

19 papers receiving 274 citations

Peers

Gemma Azaceta

IMMUN

ONCOL

GENET

Abbarna A. Cumaraswamy Canada

Sachiko Tai Japan

Samuel H. Myers Italy

Deyan Y. Yosifov Germany

Nobuaki Amino Japan

Marta Siernicka Poland

Kyriaki Tzogani Netherlands

Julie Turzanski United Kingdom

Carl W. McCrady United States

Steven M. Schmid United States

Abbarna A. Cumaraswamy Canada

Gemma Azaceta

121 ×0.9

IMMUN

116 ×0.9

ONCOL

67 ×0.9

35 ×0.8

GENET

19 ×0.6

Citations per year, relative to Gemma Azaceta Gemma Azaceta (= 1×) peers Abbarna A. Cumaraswamy

Countries citing papers authored by Gemma Azaceta

Since Specialization

Citations

This map shows the geographic impact of Gemma Azaceta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gemma Azaceta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gemma Azaceta more than expected).

Fields of papers citing papers by Gemma Azaceta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gemma Azaceta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gemma Azaceta. The network helps show where Gemma Azaceta may publish in the future.

Co-authorship network of co-authors of Gemma Azaceta

This figure shows the co-authorship network connecting the top 25 collaborators of Gemma Azaceta. A scholar is included among the top collaborators of Gemma Azaceta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gemma Azaceta. Gemma Azaceta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Cuenca, Marta, Alfonso Serrano del Valle, Gemma Azaceta, et al.. (2023). Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐X_L in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients. Molecular Oncology. 17(12). 2507–2525. 2 indexed citations

Reina-Ortiz, Chantal, Gemma Azaceta, Luis Palomera, et al.. (2022). Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma. Cells. 11(3). 392–392. 11 indexed citations

Valle, Alfonso Serrano del, Gemma Azaceta, Luis Palomera, et al.. (2022). Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis. OncoImmunology. 11(1). 2141973–2141973. 7 indexed citations

Prieto‐Torres, Lucía, Carlos Santonja, Cristina Chamizo, et al.. (2022). Granulomatous Dermatitis Heralding Myelodisplastic/Myeloproliferative Neoplasms. Neoplastic or Reactive Cells? A Study of 2 Cases. American Journal of Dermatopathology. 44(6). 456–460. 3 indexed citations

Reina-Ortiz, Chantal, Maria Rita Polo Gascón, Daniel Woods, et al.. (2020). Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Scientific Reports. 10(1). 19398–19398. 24 indexed citations

Reina-Ortiz, Chantal, Michael G. Constantinides, Jessy Présumey, et al.. (2020). Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. OncoImmunology. 10(1). 1853314–1853314. 28 indexed citations

Sánchez‐Martínez, Diego, Pilar M. Lanuza, Natalia Gómez, et al.. (2016). Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Frontiers in Immunology. 7. 454–454. 25 indexed citations

Xicoy, Blanca, Jennifer Kaivers, Ulrich Germing, et al.. (2016). Analysis of Transfusion Dependency Development and Disease Evolution in Patients with MDS with 5q- and without Transfusion Needs at Diagnosis. Blood. 128(22). 3180–3180. 1 indexed citations

Costa, Dolors, Ana Carrió, Françesc Solé, et al.. (2015). Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes. Acta Haematologica. 135(2). 94–100. 1 indexed citations

10.

Sánchez‐Martínez, Diego, Gemma Azaceta, Aura Muntasell, et al.. (2015). Human NK cells activated by EBV⁺lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. OncoImmunology. 4(3). e991613–e991613. 38 indexed citations

11.

Ramírez-Labrada, Ariel, Patricia Galán‐Malo, Gemma Azaceta, et al.. (2014). Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clinical & Translational Oncology. 17(2). 121–132. 22 indexed citations

12.

Galán‐Malo, Patricia, Ariel Ramírez-Labrada, Marta Pérez-Hernández, et al.. (2013). Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochemical Pharmacology. 87(3). 410–423. 29 indexed citations

13.

Vela, Laura, Marı́a Contel, Luis Palomera, Gemma Azaceta, & Isabel Marzo. (2011). Iminophosphorane–organogold(III) complexes induce cell death through mitochondrial ROS production. Journal of Inorganic Biochemistry. 105(10). 1306–1313. 52 indexed citations

14.

Palomera, Luis, et al.. (2002). Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.. PubMed. 87(1). 107–8. 15 indexed citations

15.

Azaceta, Gemma, et al.. (1999). Hemorheological Profile in Chronic Venous Insufficiency after Surgery. Pathophysiology of Haemostasis and Thrombosis. 29(4). 219–224. 1 indexed citations

16.

Azaceta, Gemma, et al.. (1999). Successful lipid-complexed amphotericin B treatment of Candida arthritis in a lymphoma patient.. PubMed. 66(7-9). 434–5. 10 indexed citations

17.

Azaceta, Gemma, et al.. (1998). Primary orbital lymphoma: contralateral relapse after six years in complete remission.. PubMed. 83(3). 287–287. 1 indexed citations

18.

Palomera, L., et al.. (1998). Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.. PubMed. 83(11). 1045–6. 3 indexed citations

19.

Azaceta, Gemma, et al.. (1997). [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].. PubMed. 42(5). 387–90. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact